Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 15, 2023Intelligent PharmacyOpen Access

Cardioprotective potential of Rosuvastatin against isoproterenol induced cardiac dysfunction and hypertrophy in the experimental model of rodents

View Full Paper
Ask AI
Bookmark
Share

Key result

Rosuvastatin attenuates ventricular hypertrophy, remodeling, and dysfunction in a rat model of heart failure.

Why the study?

The study was conducted to examine the protective impact of rosuvastatin on isoproterenol-induced chronic heart failure and investigate plausible related mechanisms.

Does rosuvastatin prevent cardiac dysfunction and hypertrophy in an isoproterenol-induced heart failure model in rodents?

Population

Male Sprague Dawley rats with isoproterenol-induced heart failure

Comparison

Rosuvastatin (10 mg/kg) orally vs isoproterenol alone

Design

Experimental animal study

Follow-up

14 days

Authors

RWRufaida WasimTMTarique MahmoodMSMohammed Haris Siddiqui

Discussion

Loading...

Member takes

Overview

Should not change HF practice; hypothesis-generating for statin pleiotropy in rodent models.

Structured PICO

Does rosuvastatin prevent cardiac dysfunction and hypertrophy in an isoproterenol-induced heart failure model in rodents?

P
Population
Male Sprague Dawley rats with isoproterenol-induced heart failure treated with rosuvastatin for 14 days.
I
Intervention
Rosuvastatin (10 mg/kg) orally administrated from day 1 to day 14
O
Outcome
Hypertrophy, remodeling, and dysfunction of the ventricle, hemodynamic parameters, cardiac troponin I, heart mitochondrial enzyme, lysosomal hydrolases, and pro-inflammatory cytokines levelssurrogate

Rosuvastatin demonstrated cardioprotective effects against isoproterenol-induced heart failure in a rodent model, suggesting potential pleiotropic benefits in heart failure.

Limitations

  • Further research is required to identify the precise molecular mechanisms and signalling pathways of rosuvastatin's impact on heart failure.
  • Further research is required to identify the precise molecular mechanisms and signalling pathways

Cite This Study

Wasim et al. (2023) studied Isoproterenol-induced chronic heart failure. Rosuvastatin vs. Isoproterenol alone was evaluated on Cardiac hypertrophy, remodeling, dysfunction, and biomarker levels. Rosuvastatin (10 mg/kg) significantly attenuated isoproterenol-induced ventricular hypertrophy, remodeling, and dysfunction in a rat model of heart failure.

synapsesocial.com/papers/6a204db56504ae8788d1e727https://doi.org/10.1016/j.ipha.2023.09.002
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury2013 · 46 citations
  2. 2Postconditioning with rosuvastatin reduces myocardial ischemia-reperfusion injury by inhibiting high mobility group box 1 protein expression2013 · 14 citations
  3. 3β-AR Blockers Suppresses ER Stress in Cardiac Hypertrophy and Heart Failure2011 · 80 citations
  4. 42016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure2016 · 614 citations
  5. 5The effect of fluoride on succinic oxidase system1952 · 710 citations